Immunicon Corporation Extends R&D Agreement With Pfizer Inc.

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--March 28, 2006--Immunicon Corporation (NASDAQ-NM:IMMC) announced today an extension of its Research and Development Agreement with Pfizer, Inc., under which the Company collaborates with Pfizer to develop new reagents designed to detect certain undisclosed antigens on circulating tumor cells (CTCs). The collaboration began in February 2003 and is now amended to permit the parties to initiate new clinical research studies by adding new Appendices duly signed by both parties to the Agreement. A new Phase I trial has been added to the Agreement through this mechanism and will begin enrollment immediately.